CoChat

Fluoxetine inhibited the activation of A1 reactive astrocyte in a mouse model of major depressive disorder through astrocytic 5-HT2BR/β-arrestin2 pathway

Open access
Fang, Yinquan, Ding, Xiao, Zhang, Yihe, Cai, Lei, Ge, Yuan, Ma, Kaiyang, Xu, Rong, Li, Shanshan, Song, Mengmeng, Zhu, Hong, Liu, Jiaqi, Ding, Jianhua, Lu, Ming, Hu, Gang · 2022 · Journal of Neuroinflammation

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Background: Fluoxetine, a selective serotonin reuptake inhibitor, has been reported to directly bind with 5-HT 2B receptor (5-HT 2B R), but the precise mechanisms, whereby fluoxetine confers the anti-depressive actions via 5-HT 2B R is not fully understood. Although neuroinflammation-induced A1 astrocytes are involved in neurodegenerative diseases, the role of A1 astrocyte in the pathogenesis and treatment of major depressive disorder (MDD) remains unclear. Methods: Mice were subjected to chronic mild stress (CMS) for 6 weeks and subsequently treated with fluoxetine for 4 weeks. The depressive-like and anxiety-like behaviors and the activation of A1 reactive astrocyte in hippocampus and cortex of mice were measured. Primary astrocytes were stimulated with A1 cocktail (tumor necrosis factor (TNF)-α, interleukin (IL)-1α and C1q), activated (LPS) microglia-conditioned medium (MCM) or IL-6 for 24 h and the expression of A1-special and A2-special markers were determined using RT-qPCR and western blot. The role of 5-HT 2B R in the effects of fluoxetine on A1 reactive astrocyte was measured using 5-HT 2B R inhibitor and siRNA in vitro and AAVs in vivo. The functions of downstream signaling Gq protein and β-arrestins in the effects of fluoxetine on the activation of A1 astrocyte were determined using pharmacological inhibitor and genetic knockout, respectively. Results: In this study, we found that fluoxetine inhibited the activation of A1 reactive astrocyte and reduced the abnormal behaviors in CMS mice, as well as ameliorated A1 astrocyte reactivity under three different stimulators in primary astrocytes. We also showed that astrocytic 5-HT 2B R was required in the inhibitory effects of fluoxetine on A1 reactive astrocyte in MDD in vivo and in vitro. We further found that the functions of fluoxetine in the activation of A1 astrocyte were independent of either Gq protein or β-arrestin1 in vitro. β-arrestin2 pathway was the downstream signaling of astrocytic 5-HT 2B R mediated the inhibitory effects of fluoxetine on A1 astrocyte reactivity in primary astrocytes and CMS mice, as well as the improved roles of fluoxetine in behavioral impairments of CMS mice. Conclusions: These data demonstrate that fluoxetine restricts reactive A1 astrocyte via astrocytic 5-HT 2B R/β-arrestin2 pathway in a mouse model of MDD and provide a novel therapeutic avenue for MDD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-022-02389-y

Cites

Statistics

Figures

Fig. 1 CMS-induced depressive-like behaviors, loss of astrocyte and A1 astrocyte reactivity are rescued by fluoxetine administration. C57BL/6 J mice were subjected to CMS for 6 weeks and then intraperitoneal injected with a vehicle (Control, 0.9% saline) or fluoxetine (10 mg/kg/day) for another 4 weeks. A Sucrose preference percentage during 10 weeks. B, C Immobility time of mice in TST (B) and FST (C). D, E Immunofluorescence staining (D) and area (E) of GFAP+ astrocyte in the hippocampus. F, G Immunohistochemical staining (F) and total branch number (G) of GFAP+ astrocyte in the hippocampus. H Heatmap of A1-special and A2-special transcripts in the hippocampus as analyzed by RT-qPCR. I, J Protein levels of C3 in the hippocampus. K–N Proportion of C3 (K, L) and Serping1 (M, N) in astrocyte in the hippocampus. Scar bar, 20 μm in D, K, M; Scar bar, 40 μm in F. Quantitative data are mean ± s.e. Data were analyzed using two-way ANOVA, then combined with Tukey’s multiple comparison to assess the differences between groups. A, B: n = 8 per group; C: n = 9 CON with saline and CMS with FLX, n = 8 CMS with saline and CON with FLX; D–N n = 4 per group; biologically independent animals. A, H: **P < 0.01, and ***P < 0.001 vs respective Control mice treated with saline; #P < 0.05, and ###P < 0.001 vs CMS mice treated with saline. B–G, J, L, N: *P < 0.05, **P < 0.01, and ***P < 0.001
Fig. 1 CMS-induced depressive-like behaviors, loss of astrocyte and A1 astrocyte reactivity are rescued by fluoxetine administration. C57BL/6 J mice were subjected to CMS for 6 weeks and then intraperitoneal injected with a vehicle (Control, 0.9% saline) or fluoxetine (10 mg/kg/day) for another 4 weeks. A Sucrose preference percentage during 10 weeks. B, C Immobility time of mice in TST (B) and FST (C). D, E Immunofluorescence staining (D) and area (E) of GFAP+ astrocyte in the hippocampus. F, G Immunohistochemical staining (F) and total branch number (G) of GFAP+ astrocyte in the hippocampus. H Heatmap of A1-special and A2-special transcripts in the hippocampus as analyzed by RT-qPCR. I, J Protein levels of C3 in the hippocampus. K–N Proportion of C3 (K, L) and Serping1 (M, N) in astrocyte in the hippocampus. Scar bar, 20 μm in D, K, M; Scar bar, 40 μm in F. Quantitative data are mean ± s.e. Data were analyzed using two-way ANOVA, then combined with Tukey’s multiple comparison to assess the differences between groups. A, B: n = 8 per group; C: n = 9 CON with saline and CMS with FLX, n = 8 CMS with saline and CON with FLX; D–N n = 4 per group; biologically independent animals. A, H: **P < 0.01, and ***P < 0.001 vs respective Control mice treated with saline; #P < 0.05, and ###P < 0.001 vs CMS mice treated with saline. B–G, J, L, N: *P < 0.05, **P < 0.01, and ***P < 0.001CC BY · PubMed Central
Fig.2 Fluoxetine inhibits the production of A1 reactive astrocytes under three different stimulators. A, B Heatmap of A1-special and A2-special transcripts in primary astrocytes after A1 cocktail (IL-1α plus TNF-α plus C1q) stimulation (A) or activated (LPS)-MCM treatment (B) for 24 h as analyzed by RT-qPCR. C–F Protein levels of C3 in astrocyte after A1 cocktail stimulation (C, D) or LPS-MCM treatment (E, F) for 24 h. G Heatmap of A1-special and A2-special transcripts in astrocyte after IL-6 stimulation for 24 h as analyzed by RT-qPCR. H, I Protein levels of C3 in astrocyte after IL-6 stimulation for 24 h. Quantitative data are mean ± s.e. Data were analyzed using two-way ANOVA, then combined with Tukey’s multiple comparison to assess the differences between groups. All data represent the results of three independent experiments. A, B, G: *P < 0.05, **P < 0.01, and ***P < 0.001 vs Control cells treated with PBS (A, G) or non-activated MCM (B); #P < 0.05, ##P < 0.01, and ###P < 0.001 vs Control cells treated with A1 (A), activated (LPS) MCM (B) or IL-6 (G) stimulation. D, F, I: *P < 0.05, **P < 0.01, and ***P < 0.001
Fig.2 Fluoxetine inhibits the production of A1 reactive astrocytes under three different stimulators. A, B Heatmap of A1-special and A2-special transcripts in primary astrocytes after A1 cocktail (IL-1α plus TNF-α plus C1q) stimulation (A) or activated (LPS)-MCM treatment (B) for 24 h as analyzed by RT-qPCR. C–F Protein levels of C3 in astrocyte after A1 cocktail stimulation (C, D) or LPS-MCM treatment (E, F) for 24 h. G Heatmap of A1-special and A2-special transcripts in astrocyte after IL-6 stimulation for 24 h as analyzed by RT-qPCR. H, I Protein levels of C3 in astrocyte after IL-6 stimulation for 24 h. Quantitative data are mean ± s.e. Data were analyzed using two-way ANOVA, then combined with Tukey’s multiple comparison to assess the differences between groups. All data represent the results of three independent experiments. A, B, G: *P < 0.05, **P < 0.01, and ***P < 0.001 vs Control cells treated with PBS (A, G) or non-activated MCM (B); #P < 0.05, ##P < 0.01, and ###P < 0.001 vs Control cells treated with A1 (A), activated (LPS) MCM (B) or IL-6 (G) stimulation. D, F, I: *P < 0.05, **P < 0.01, and ***P < 0.001CC BY · PubMed Central
Fig.3 5-HT2BR is required for the effects of fluoxetine on activation of A1 astrocyte in vitro. A Expression of 5-HT2BR on primary cultured microglia, astrocyte and neuron. B Expression of 5-HT2BR on astrocyte in the hippocampus. Similar results were obtained in 3 separate experiments. C, D Effects of 5-HT2BR inhibitor, RS127445, on the expression of A1-special transcripts in astrocytes with or without fluoxetine treatment after A1 cocktail C or IL-6 D stimulation for 24 h. E Effects of 5-HT2BR knockdown on the mRNA levels of A1-special markers in astrocytes with or without fluoxetine treatment after IL-6 stimulation for 24 h. Scale bars, 20 µm in B. Quantitative data are mean ± s.e. Data were analyzed using two-way ANOVA, then combined with Tukey’s multiple comparison to assess the differences between groups. All data represent the results of three independent experiments. C–E: **P < 0.01, and ***P < 0.001 vs respective Control cells treated with PBS; #P < 0.05, ##P < 0.01, and ###P < 0.001 vs Control cells treated with A1 (C) or IL-6 (D, E) stimulation; $P < 0.05, $$P < 0.01, and $$$P < 0.001
Fig.3 5-HT2BR is required for the effects of fluoxetine on activation of A1 astrocyte in vitro. A Expression of 5-HT2BR on primary cultured microglia, astrocyte and neuron. B Expression of 5-HT2BR on astrocyte in the hippocampus. Similar results were obtained in 3 separate experiments. C, D Effects of 5-HT2BR inhibitor, RS127445, on the expression of A1-special transcripts in astrocytes with or without fluoxetine treatment after A1 cocktail C or IL-6 D stimulation for 24 h. E Effects of 5-HT2BR knockdown on the mRNA levels of A1-special markers in astrocytes with or without fluoxetine treatment after IL-6 stimulation for 24 h. Scale bars, 20 µm in B. Quantitative data are mean ± s.e. Data were analyzed using two-way ANOVA, then combined with Tukey’s multiple comparison to assess the differences between groups. All data represent the results of three independent experiments. C–E: **P < 0.01, and ***P < 0.001 vs respective Control cells treated with PBS; #P < 0.05, ##P < 0.01, and ###P < 0.001 vs Control cells treated with A1 (C) or IL-6 (D, E) stimulation; $P < 0.05, $$P < 0.01, and $$$P < 0.001CC BY · PubMed Central
Fig. 4 Astrocytic 5-HT2BR knockdown blocks effects of fluoxetine on CMS-induced depressive-like behaviors and A1 astrocyte reactivity. A Sucrose preference percentage of mice during 10 week treatment after AAV injection for 4 weeks. B Immobility time of mice in TST and FST. C, D Expression of C3 on astrocyte in the hippocampus DG of CON and CMS mice after AAV injection. E, F Protein levels of C3 in the hippocampus. G The levels of A1-special genes in the hippocampus. Scar bar, 20 μm in C. Quantitative data are mean ± s.e. Data were analyzed using two-way ANOVA, then combined with Tukey’s multiple comparison to assess the differences between groups. A, B: n = 9 CON with Control AAV and saline; n = 8 (B), n = 9 (A) CON with Control AAV and FLX; n = 8 (B-FST), n = 10 (A, B-TST) CMS with Control AAV and saline; n = 8 (B), n = 10 (A) CMS with Control AAV and FLX; n = 8 CON with mHT2BR AAV and saline; n = 8 CON with mHT2BR AAV and FLX; n = 8 (B-TST), n = 9 (A, B-FST) CMS with mHT2BR AAV and saline; n = 8 CMS with mHT2BR AAV and FLX; C–G: n = 4 per group; biologically independent animals. A: ***P < 0.001 vs respective Control mice treated with saline; ###P < 0.001 vs CMS mice injected with Control AAV and treated with saline; $$P < 0.01vs CMS mice injected with Control AAV and treated with fluoxetine; B, D, F and G: *P < 0.05, **P < 0.01, and ***P < 0.001 vs respective Control mice treated with saline; #P < 0.05, ##P < 0.01, and ###P < 0.001 vs CMS mice injected with Control AAV and treated with saline; $P < 0.05, and $$$P < 0.001
Fig. 4 Astrocytic 5-HT2BR knockdown blocks effects of fluoxetine on CMS-induced depressive-like behaviors and A1 astrocyte reactivity. A Sucrose preference percentage of mice during 10 week treatment after AAV injection for 4 weeks. B Immobility time of mice in TST and FST. C, D Expression of C3 on astrocyte in the hippocampus DG of CON and CMS mice after AAV injection. E, F Protein levels of C3 in the hippocampus. G The levels of A1-special genes in the hippocampus. Scar bar, 20 μm in C. Quantitative data are mean ± s.e. Data were analyzed using two-way ANOVA, then combined with Tukey’s multiple comparison to assess the differences between groups. A, B: n = 9 CON with Control AAV and saline; n = 8 (B), n = 9 (A) CON with Control AAV and FLX; n = 8 (B-FST), n = 10 (A, B-TST) CMS with Control AAV and saline; n = 8 (B), n = 10 (A) CMS with Control AAV and FLX; n = 8 CON with mHT2BR AAV and saline; n = 8 CON with mHT2BR AAV and FLX; n = 8 (B-TST), n = 9 (A, B-FST) CMS with mHT2BR AAV and saline; n = 8 CMS with mHT2BR AAV and FLX; C–G: n = 4 per group; biologically independent animals. A: ***P < 0.001 vs respective Control mice treated with saline; ###P < 0.001 vs CMS mice injected with Control AAV and treated with saline; $$P < 0.01vs CMS mice injected with Control AAV and treated with fluoxetine; B, D, F and G: *P < 0.05, **P < 0.01, and ***P < 0.001 vs respective Control mice treated with saline; #P < 0.05, ##P < 0.01, and ###P < 0.001 vs CMS mice injected with Control AAV and treated with saline; $P < 0.05, and $$$P < 0.001CC BY · PubMed Central
Fig. 5 Functions of fluoxetine in A1 astrocyte reactivity are independent of classical G protein pathways. A, B Effects of the inhibitor of Gq protein, YM-254890 on the mRNA levels of A1-special markers in astrocytes with or without fluoxetine treatment after A1 (A) or IL-6 (B) stimulation. Quantitative data are mean ± s.e. Data were analyzed using two-way ANOVA, then combined with Tukey’s multiple comparison to assess the differences between groups. All data represent the results of three independent experiments. **P < 0.01, and ***P < 0.001 vs respective Control cells treated with PBS; ##P < 0.01, and ###P < 0.001 vs Control cells treated with A1 (A) or IL-6 (B) stimulation
Fig. 5 Functions of fluoxetine in A1 astrocyte reactivity are independent of classical G protein pathways. A, B Effects of the inhibitor of Gq protein, YM-254890 on the mRNA levels of A1-special markers in astrocytes with or without fluoxetine treatment after A1 (A) or IL-6 (B) stimulation. Quantitative data are mean ± s.e. Data were analyzed using two-way ANOVA, then combined with Tukey’s multiple comparison to assess the differences between groups. All data represent the results of three independent experiments. **P < 0.01, and ***P < 0.001 vs respective Control cells treated with PBS; ##P < 0.01, and ###P < 0.001 vs Control cells treated with A1 (A) or IL-6 (B) stimulationCC BY · PubMed Central
Fig. 6 β-arrestin 2, rather than β-arrestin 1 participates in the effects of fluoxetine on A1 reactive astrocytes. A, B Effects of β-arrestin 1 or β-arrestin 2 knockout on the levels of A1-special genes in astrocytes with or without fluoxetine treatment after A1 cocktail (A) or IL-6 (B) stimulation. Quantitative data are mean ± s.e. Data were analyzed using two-way ANOVA, then combined with Tukey’s multiple comparison to assess the differences between groups. All data represent the results of three independent experiments. *P < 0.05, and ***P < 0.001 vs respective Control cells treated with PBS; #P < 0.05, and ###P < 0.001 vs WT Control cells treated with A1 (A) or IL-6 (B) stimulation; $P < 0.05, and $$$P < 0.001
Fig. 6 β-arrestin 2, rather than β-arrestin 1 participates in the effects of fluoxetine on A1 reactive astrocytes. A, B Effects of β-arrestin 1 or β-arrestin 2 knockout on the levels of A1-special genes in astrocytes with or without fluoxetine treatment after A1 cocktail (A) or IL-6 (B) stimulation. Quantitative data are mean ± s.e. Data were analyzed using two-way ANOVA, then combined with Tukey’s multiple comparison to assess the differences between groups. All data represent the results of three independent experiments. *P < 0.05, and ***P < 0.001 vs respective Control cells treated with PBS; #P < 0.05, and ###P < 0.001 vs WT Control cells treated with A1 (A) or IL-6 (B) stimulation; $P < 0.05, and $$$P < 0.001CC BY · PubMed Central
Fig.7 β-arrestin 2 depletion reverses roles of fluoxetine in depressive-like behaviors and A1 astrocyte reactivity in CMS mice. A Sucrose preference percentage of WT and β-arrestin 2 knockout mice during 10 week treatment. B Immobility time of mice in TST and FST. C, D Expression of C3 on astrocyte in the hippocampus of WT and β-arrestin 2−/− mice with or without fluoxetine treatment. E, F Protein levels of C3 in the hippocampus. G Levels of A1-special genes in the hippocampus. Scar bar, 20 μm in C. Quantitative data are mean ± s.e. Data were analyzed using two-way ANOVA, then combined with Tukey’s multiple comparison to assess the differences between groups. A, B: n = 8 (A, B-FST), n = 9 (B-TST) WT CON with saline; n = 8 WT CON with FLX; n = 8 (A), n = 10 (B) WT CMS with saline; n = 8 (B-FST), n = 9 (A, B-TST) WT CMS with FLX; n = 8 (A), n = 9 (B-TST), n = 10 (B-FST) β-arrestin 2−/− CON with saline; n = 8 (A, B-FST), n = 10 (B-TST) β-arrestin 2−/− CON with FLX; n = 8 (A, B-FST), n = 9 (B-TST) β-arrestin 2−/− CMS with saline; n = 8 β-arrestin 2−/− CMS with FLX; C-G: n = 4 per group; biologically independent animals. A: ***P < 0.001 vs respective Control mice treated with saline; ###P < 0.001 vs WT CMS mice treated with saline; $$P < 0.01vs WT CMS mice treated with fluoxetine; B, D, F and G: ***P < 0.001 vs respective Control mice treated with saline; ###P < 0.001 vs WT CMS mice treated with saline; $P < 0.05, $$$P < 0.001
Fig.7 β-arrestin 2 depletion reverses roles of fluoxetine in depressive-like behaviors and A1 astrocyte reactivity in CMS mice. A Sucrose preference percentage of WT and β-arrestin 2 knockout mice during 10 week treatment. B Immobility time of mice in TST and FST. C, D Expression of C3 on astrocyte in the hippocampus of WT and β-arrestin 2−/− mice with or without fluoxetine treatment. E, F Protein levels of C3 in the hippocampus. G Levels of A1-special genes in the hippocampus. Scar bar, 20 μm in C. Quantitative data are mean ± s.e. Data were analyzed using two-way ANOVA, then combined with Tukey’s multiple comparison to assess the differences between groups. A, B: n = 8 (A, B-FST), n = 9 (B-TST) WT CON with saline; n = 8 WT CON with FLX; n = 8 (A), n = 10 (B) WT CMS with saline; n = 8 (B-FST), n = 9 (A, B-TST) WT CMS with FLX; n = 8 (A), n = 9 (B-TST), n = 10 (B-FST) β-arrestin 2−/− CON with saline; n = 8 (A, B-FST), n = 10 (B-TST) β-arrestin 2−/− CON with FLX; n = 8 (A, B-FST), n = 9 (B-TST) β-arrestin 2−/− CMS with saline; n = 8 β-arrestin 2−/− CMS with FLX; C-G: n = 4 per group; biologically independent animals. A: ***P < 0.001 vs respective Control mice treated with saline; ###P < 0.001 vs WT CMS mice treated with saline; $$P < 0.01vs WT CMS mice treated with fluoxetine; B, D, F and G: ***P < 0.001 vs respective Control mice treated with saline; ###P < 0.001 vs WT CMS mice treated with saline; $P < 0.05, $$$P < 0.001CC BY · PubMed Central
Fig.8 Schematic diagram showing inhibitory effects of fluoxetine on of A1 astrocyte reactivity in depression. Fluoxetine (FLX) administration inhibits the activation of A1 astrocytes in CMS mice and primary astrocytes via 5-HT2BR/β-arrestin2 pathway not Gq protein pathway in astrocytes, which could improve behavioral impairments of CMS mice
Fig.8 Schematic diagram showing inhibitory effects of fluoxetine on of A1 astrocyte reactivity in depression. Fluoxetine (FLX) administration inhibits the activation of A1 astrocytes in CMS mice and primary astrocytes via 5-HT2BR/β-arrestin2 pathway not Gq protein pathway in astrocytes, which could improve behavioral impairments of CMS miceCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 68 · Cited by 96

Metadata

Authors
Fang, Y., Ding, X., Zhang, Y., Cai, L., Ge, Y., Ma, K., Xu, R., Li, S., Song, M., Zhu, H., Liu, J., Ding, J., Lu, M., & Hu, G.
Affiliations
  • Nanjing Medical University (CN)
  • Nanjing University of Chinese Medicine (CN)
Corresponding author
Hu, Gang
Venue
Journal of Neuroinflammation
Published
2022-01-29
Volume
19
Issue
1
Pages
23-23
ISSN
1742-2094 (ISSN-L)
OpenAlex
W4210544342
Cited by
96
References
68
Citations by year
2026: 19 · 2025: 34 · 2024: 20 · 2023: 14 · 2022: 9
FWCI
6.69
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Neuroinflammation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81630099, 81991523, 81703488)
  • Drug Innovation Major Project (2018ZX09711001-003-007)
  • Natural Science Foundation of the Basic Research Program of Jiangsu Province (BK20171061)
Topics
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
fluoxetine, major depressive disorder, 5-HT2B receptor, β-arrestin2, chronic mild stress, neuroinflammation, Gq protein, hippocampus, astrocyte activation, anxiety-like behavior, depression-like behavior, interleukin-6, TNF-α, C1q
MeSH terms
beta-Arrestin 2, Animals, Astrocytes, Major Depressive Disorder, Fluoxetine, Serotonin, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fluoxetine inhibited the activation of A1 reactive astrocyte in a mouse model of major depressive disorder through astrocytic 5-HT2BR/β-arrestin2 pathway. https://app.cochat.ai/papers/10.1186/s12974-022-02389-y
The paper
Fang, Y., Ding, X., Zhang, Y., Cai, L., Ge, Y., Ma, K., Xu, R., Li, S., Song, M., Zhu, H., Liu, J., Ding, J., Lu, M., & Hu, G. (2022). Fluoxetine inhibited the activation of A1 reactive astrocyte in a mouse model of major depressive disorder through astrocytic 5-HT2BR/β-arrestin2 pathway. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-022-02389-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.